In Person
Treatments at The Menninger Clinic: Foundations and the Future

Rapid Targeted TMS: New Hope for Depression Treatment

Neil Puri, MD
|

Information

Date & Time

Learning Objectives

Participants will be able to:

  • Summarize the need for new treatments for major depressive disorder.

  • Describe new rTMS protocol, fMRI guided accelerated prolonged iTBS.

  • Identify the effects of fMRI guided accelerated prolonged iTBS for depression.

  • Discuss emerging uses for fMRI guided accelerated prolonged iTBS.

Educational Goal

Depression has a large impact on society. Suicide is a leading cause of death. Typical treatments for depression and suicide are not fully effective. fMRI guided accelerated prolonged iTBS is a new form of treatment without outstanding results and, hence, providers should be aware of it and recommend it for their patients suffering from depression.

Description

Depression has a large impact on society, and suicide is a leading cause of death. However, typical treatments for depression and suicide are often not fully effective. Recent evidence, however, shows high success rates for a new TMS (Transcranial Magnetic Stimulation) protocol: fMRI guided accelerated prolonged iTBS. This presentation will review this new protocol, its evidence-base, and how it can help treatment resistant depression.

Target Audience

  • Counselor
  • Marriage & Family Therapist
  • Medical Doctor
  • Nurse Practitioner
  • Psychologist
  • Registered Nurse
  • Social Worker
  • Substance Use Disorder Professionals

Presenters

Neil Puri, MD
Dr. Puri is the Medical Director of the Outpatient Division at The Menninger Clinic and the Director of The Menninger Clinic’s Center for Brain Stimulation. He is also the director of graduate medical education at The Menninger Clinic. Dr. Puri’s work is focused on treatment resistant depression and patients with high suicidal drive. The Center for Brain Stimulation provides ECT, Ketamine, TMS, and fMRI guided TMS treatments. The Center is also involved in research on psilocybin, digital therapeutics, TMS, and ECT.